We are experts in myeloma…
it’s all we do

 

Our singular focus on myeloma ensures that we bring unparalleled expertise and dedication to everything we do

 

From actionable insights to strategic engagement with leading KOLs and community clinicians, our full suite of  services empowers you to lead in the myeloma market

InSights

MYinSIGHTS provides real-time insights to data being presented at conferences or from the latest publications. Gain an understanding of how the experts view the data.

MYConference Targeted Reports. Collecting insights at medical conferences shouldn’t be hard. MYELOMA360 makes it easy

Engagements

MYBOARD is a new format for Advisory Boards.

In place of single company events, MYBoard is an independent full day advisory board fully managed by MYELOMA360, with four 2-hour time slots for multiple companies, allowing for a focused, efficient, dedicated session to generate insights around your strategic objectives.

Strategy & Consulting

We are a team of seasoned biopharmaceutical specialists dedicated to helping companies strategize and plan their marketing, clinical development and medical affairs activities.

Our expertise is focused in myeloma across the full development lifecycle, allowing us to provide tailored solutions to drive your company’s success.

Everything you need to navigate the myeloma market

Latest insights

Myeloma News

FDA Approved NDA for Aficamten to Treat Patients With Obstructive Hypertrophic Cardiomyopathy

Source: Pharmacy Times articles Aficamten, a cardiac myosin inhibitor, gains FDA approval, offering hope for improved cardiovascular health in patients with obstructive hypertrophic cardiomyopathy. Read More
Read More

Evaluation of Antibiotic Administration Surrounding Interventional Radiology Procedures

Source: Pharmacy Times articles Implementation of a guidance document for periprocedural antibiotic prophylaxis resulted in improved appropriateness of antibiotic dose, selection, and duration for interventional radiology procedures. Read More
Read More

Adding Pertuzumab to Trastuzumab and Chemotherapy Reduced Risk of Death by 17% in HER2+ Breast Cancer

Source: Pharmacy Times articles New data reveals that combining pertuzumab with trastuzumab significantly improves survival rates in HER2+ breast cancer patients, reducing death risk by 17%. Read More
Read More

Several Comorbidities Found to Reduce Likelihood of Pneumococcal Vaccination, While Use of Implantable Devices Heightens Odds

Source: Pharmacy Times articles A new study reveals that heart failure patients with implantable devices are more likely to receive the pneumococcal conjugate vaccine 13, impacting vaccination rates and mortality. Read More
Read More

Omalizumab: An All-in-One Allergy Wonder Drug?

Source: Pharmacy Times articles Omalizumab expands its role in allergy management, now FDA-approved for food allergies, showcasing potential for broader applications in allergic rhinitis. Read More
Read More

Durvalumab Regimen Improves Disease-Free Survival in High-Risk Non-Muscle-Invasive Bladder Cancer

Source: Pharmacy Times articles The regimen, which consists of durvalumab and Bacillus Calmette-Guerin, offers new hope to patients with high-risk non-muscle-invasive bladder cancer. Read More
Read More
Latest Data

Latest Publications

Sarcopenia and clinical outcomes in lymphoma and multiple myeloma patients receiving hematopoietic cell transplantation: a systematic review and meta-analysis

Int J Hematol. 2025 May 13. doi: 10.1007/s12185-025-03998-y. Online ahead of print. ABSTRACT...
Read More

Effectiveness and safety of teclistamab for relapsed or refractory multiple myeloma: a systematic review and meta-analysis

Front Immunol. 2025 Apr 25;16:1565407. doi: 10.3389/fimmu.2025.1565407. eCollection 2025. ABSTRACT...
Read More

Allogeneic versus autologous stem cell transplantation after relapsing following first line autologous transplantation for multiple myeloma: A systematic review

Cancer. 2025 May 15;131(10):e35896. doi: 10.1002/cncr.35896. ABSTRACT BACKGROUND: Allogeneic stem...
Read More

Single-Nucleotide Polymorphisms Related to Multiple Myeloma Risk: A Systematic Review and Meta-Analysis

Int J Mol Sci. 2025 Apr 4;26(7):3369. doi: 10.3390/ijms26073369. ABSTRACT Multiple myeloma ranks...
Read More

Unveiling Extramedullary Myeloma Immune Microenvironment: A Systematic Review

Cancers (Basel). 2025 Mar 24;17(7):1081. doi: 10.3390/cancers17071081. ABSTRACT...
Read More

Real-World Evidence Evaluating Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Systematic Literature Review

Cancers (Basel). 2025 Apr 5;17(7):1235. doi: 10.3390/cancers17071235. ABSTRACT Background:...
Read More

Email

info@myeloma360.com